Hainan Poly Pharm Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Hainan Poly Pharm.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 14.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Hainan Poly Pharm. Co., Ltd (SZSE:300630) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Feb 12
Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 26% Dip In Price Shows Sentiment Is Matching Revenues
Dec 18Hainan Poly Pharm (SZSE:300630) Is Making Moderate Use Of Debt
Dec 02What Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 46% Share Price Gain Is Not Telling You
Oct 08Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Aug 16It's Down 27% But Hainan Poly Pharm. Co., Ltd (SZSE:300630) Could Be Riskier Than It Looks
Apr 21A Piece Of The Puzzle Missing From Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 27% Share Price Climb
Mar 06In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hainan Poly Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 1,307 | -106 | -322 | -198 | N/A |
| 6/30/2024 | 1,272 | -68 | -279 | -174 | N/A |
| 3/31/2024 | 1,396 | 86 | -301 | -54 | N/A |
| 12/31/2023 | 1,304 | 86 | -435 | 113 | N/A |
| 9/30/2023 | 872 | -67 | -426 | 283 | N/A |
| 6/30/2023 | 1,294 | 104 | -504 | 337 | N/A |
| 3/31/2023 | 1,466 | 200 | -837 | 261 | N/A |
| 12/31/2022 | 1,619 | 295 | -809 | 228 | N/A |
| 9/30/2022 | 1,743 | 482 | -869 | 83 | N/A |
| 6/30/2022 | 1,681 | 479 | -950 | 166 | N/A |
| 3/31/2022 | 1,603 | 457 | -689 | 168 | N/A |
| 1/1/2022 | 1,509 | 417 | -647 | 157 | N/A |
| 9/30/2021 | 1,543 | 513 | -737 | 380 | N/A |
| 6/30/2021 | 1,410 | 474 | -571 | 343 | N/A |
| 3/31/2021 | 1,291 | 449 | -495 | 337 | N/A |
| 12/31/2020 | 1,189 | 407 | -504 | 332 | N/A |
| 9/30/2020 | 1,124 | 380 | -385 | 251 | N/A |
| 6/30/2020 | 1,000 | 340 | -356 | 228 | N/A |
| 3/31/2020 | 964 | 311 | -355 | 217 | N/A |
| 12/31/2019 | 950 | 301 | -187 | 215 | N/A |
| 9/30/2019 | 830 | 266 | -161 | 21 | N/A |
| 6/30/2019 | 725 | 231 | -197 | 102 | N/A |
| 3/31/2019 | 687 | 220 | -140 | 98 | N/A |
| 12/31/2018 | 624 | 181 | -157 | 95 | N/A |
| 9/30/2018 | 528 | 159 | -185 | 206 | N/A |
| 6/30/2018 | 445 | 137 | N/A | 99 | N/A |
| 3/31/2018 | 371 | 119 | N/A | 95 | N/A |
| 12/31/2017 | 325 | 98 | N/A | 94 | N/A |
| 9/30/2017 | 298 | 89 | N/A | 84 | N/A |
| 6/30/2017 | 275 | 78 | N/A | 74 | N/A |
| 3/31/2017 | 260 | 72 | N/A | 56 | N/A |
| 12/31/2016 | 248 | 70 | N/A | 56 | N/A |
| 6/30/2016 | 214 | 56 | N/A | 43 | N/A |
| 3/31/2016 | 193 | 50 | N/A | 47 | N/A |
| 12/31/2015 | 203 | 51 | N/A | 58 | N/A |
| 12/31/2014 | 165 | 37 | N/A | 57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 300630's forecast earnings growth is above the savings rate (2.7%).
Earnings vs Market: Insufficient data to determine if 300630's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 300630's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 300630's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 300630's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 300630's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 16:07 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hainan Poly Pharm. Co., Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhizhong Jing | China Merchants Securities Co. Ltd. |
| Jiaxi Xu | Industrial Securities Co. Ltd. |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |